Impedimed Limited · ASX:IPD
Impedimed — Investor Presentation (February 2016)
23 slides from Impedimed's investor presentation, Feb 1, 2016
Slide 1: ImpediMed Investor Presentation February 2016
® For personal use only ASX:IPD February 2016
Slide 2: Disclaimer
Disclaimer The material contained in this document is a presentation of general information about the activities of ImpediMed Limited (“ImpediMed”) current as at the date of this presentation. For personal use only The information is provided in a summary form, does not purport to be complete and sh
Slide 3: Investment Summary
Investment Summary Proven, Proprietary Technology, IPD’s Bioimpedance Spectroscopy (BIS) — provides a simple, accurate, non-invasive system for precisely measuring and monitoring tissue composition and fluid status For personal use only IPD’s BIS Platform — provides accurate and actionable data to c
Slide 4: Core Technology – Bioimpedance Spectroscopy (BIS)
Core Technology – Bioimpedance Spectroscopy (BIS) Simple and Sophisticated Method for Measuring Fluid and Tissue Composition Bioimpedance spectroscopy — a rapid, non-invasive system that provides highly accurate data For personal use only Low Frequency Fluid Unique Spectra Fat Impedance Current pass
Slide 5: IPD's "Game Changing" Platform Technology
IPD’s “Game Changing” Platform Technology • Informative – 256 frequency spectra provides detailed For personal use only measurements of muscle, fluid, and fat • Simple to Use – easy placement of electrodes • Fast – 5 to10 mins to measure • Non-invasive – no dyes or radiation • Safe – no safety conce
Slide 6: First Application – L-Dex for the Early Detection of Lymphoedema
First Application – L-Dex for the Early Detection of Lymphoedema Lymphoedema is a leading post-surgical complication for many breast cancer patients and greatly impacts quality of life Simple and accurate measurement of fluid in limbs allows early detection and intervention For personal use only 1.
Slide 7: National Launch Progressing as Planned
National Launch Progressing as Planned 2015 2015 For personal use only • US Commercial launch of L-Dex commenced December 2015 2016 • Establish integrated presence in 50 targeted high value top tier cancer centres - Begin with breast cancer lymphoedema screening (NCCN Guidelines) - Integrate into El
Slide 8: Business Update
Business Update • Current customer patient assessment trends are Launch of New Website strong For personal use only Adoption continues to expand • 50 Targeted account update January showed marked increase in sales momentum with important target institutions added Multiple devices ordered from a numb
Slide 9: Heart Failure — Large and Compelling Opportunity
Heart Failure — Large and Compelling Opportunity American Heart Association Definition: For personal use only Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body's needs for blood and oxygen At first the heart tries to m
Slide 10: Heart Failure is a Major Burden on US Population and Healthcare System
Heart Failure is a Major Burden on US Population and Healthcare System CHF is among the most expensive Medicare (CMS) penalises hospitals for For personal use only diseases for Medicare unplanned readmissions • Estimated 5.7 million people in the • 24% of heart failure patients are US have heart fai
Slide 11: Current Heart Failure Monitoring Methods – Inaccurate or Invasive and Expensive
Current Heart Failure Monitoring Methods – Inaccurate or Invasive and Expensive For personal use only Method Measurement Brought on by The assessment of fluid burden is critical to the management of CHF 2 kilograms gained patients Weight Scale Weight gain Fluid burden in 2 days • Current practice is
Slide 12: Optimising Outcomes for Heart Failure Patients
Optimising Outcomes for Heart Failure Patients For personal use only % of Patient HF • Class III/IV HF patients account for the majority of Population Classification (est) the annual HF hospital readmissions Class I 35% • Reducing these readmission rates would have a Class II 35% profound impact on
Slide 13: ImpediMed's Next Generation BIS Technology for CHF Patient Management
ImpediMed’s Next Generation BIS Technology – Simple and Sophisticated Tool for CHF Patient Management • True whole body measurement — allows for complete and For personal use only accurate BIS measurements • Segmental measurements — provides clinicians critical data on limb, trunk, and whole body fl
Slide 14: Heart Failure Regulatory Pathway is Established and Achievable
Heart Failure Regulatory Pathway is Established and Achievable Regulatory • FDA Clearance For personal use only • IPD’s current BIS device cleared for monitoring fluid and tissue composition in both clinical and at-home settings • CHF BIS device — traditional 510(k) application (IPD predicate device
Slide 15: Noted Medical Advisory Board Providing Guidance
Noted Medical Advisory Board Providing Guidance For personal use only Advisory Board Members and Clinical Research Team Paul Friedman, MD, Vice Chair, Department of Cardiovascular Medicine, Medical Director, Remote Monitoring, Mayo Clinic Roy Small, MD, FACC, FSCAI, Medical Director of Clinical Rese
Slide 16: Potential CHF Business Model
Potential CHF Business Model • Initial focus on Class III CHF patients For personal use only - Estimated at 25% of US 5.7 million CHF patients - Goal is to monitor and manage the disease progression for Class III patients • Initial phase of commercial plan focused on Class III CHF patients - Baselin
Slide 17: Important Milestones Next Months
Important Milestones Next 18 Months • Regular updates on US L-Dex adoption and sales For personal use only • Progress on inclusion of lymphoedema in additional cancer guidelines • First release of post-approval clinical data to drive adoption and private payor coverage • Private payors to begin cove
Slide 18: Fluid: The 5th Primary Vital Sign
® For personal use only Fluid The 5th Primary Vital Sign ™
Slide 19: Appendix
For personal use only Appendix
Slide 20: Management Team Has Deep and Broad Commercialisation Experience
Management Team Has Deep and Broad Commercialisation Experience Frank Vicini, MD •Joined September 2014 Chief Medical Officer •25+ years as radiation oncologist For personal use only •Completed his fellowship at Harvard Medical School, has authored over 200 peer reviewed publications, and participat
Slide 21: Board of Directors
Board of Directors Cherrell Hirst AO • On Board since 2005 FTSE, MBBS, BEdSt, D.Univ • Appointed Non-Executive Chairman in Nov 2011 (Hon), FAICD For personal use only • Leading medical practitioner in breast cancer screening/diagnosis Non-Executive Chairman • Currently Chairman of Tissue Therapies L
Slide 22: Corporate Overview
Corporate Overview Share Price Performance – 1 Year (January 2016) ASX: IPD - 28 Jan • ASX listed (October 2007) 1.06 Price Change -0.070 (6.195%) For personal use only • S&P/ASX 300 – added March 2015 • Operations in US (San Diego) and Australia (Brisbane) • 55 staff (49 US and 6 AU) • Market capit
Slide 23: Financial Year to Date (31 December 2015)
Financial Year to Date (31 December 2015) 31 December – AUD 1H FY2016 1H FY2015 % Change (preliminary and unaudited) For personal use only $000 $000 Lymphoedema Revenue 1,361 753 81% Body Composition Revenue 331 396 16% Test & Measurement Revenue 1,019 935 9% Total Group Revenue 2,711 2,084 30% Oper